Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer.
Breast cancer
Neuropilin-1
Prognosis
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
17
02
2021
accepted:
07
04
2021
pubmed:
23
4
2021
medline:
10
7
2021
entrez:
22
4
2021
Statut:
ppublish
Résumé
Neuropilin-1 (NRP-1) is a transmembrane protein that acts as a multifunctional non-tyrosine kinase receptor with an established role in development and immunity. NRP-1 also regulates tumor biology, and high expression levels of tissue NRP-1 have been associated with a poor prognosis. Recently, ELISA-based quantification of soluble NRP-1 (sNRP-1) has become available, but little is known about the prognostic value of sNRP-1 in malignancies. We measured sNRP-1 in the serum of 509 patients with primary early breast cancer (BC) at the time of diagnosis using ELISA. Mean serum values of sNRP-1 were 1.88 ± 0.52 nmol/l (= 130.83 ± 36.24 ng/ml). SNRP-1 levels weakly correlated with age, and were higher in peri- and postmenopausal patients compared to premenopausal patients, respectively (p < 0.0001). Low levels of sNRP-1 were associated with a significant survival benefit compared to high sNRP-1 levels at baseline (p = 0.005; HR 1.94; 95%CI 1.23-3.06). These findings remained significant after adjustment for tumor stage including lymph node involvement, grading, hormone receptor, HER2 status, and age (p = 0.022; HR 1.78; 95%CI 1.09-2.91). Our findings warrant further investigations into the prognostic and therapeutic potential of sNRP-1 in BC.
Sections du résumé
BACKGROUND
BACKGROUND
Neuropilin-1 (NRP-1) is a transmembrane protein that acts as a multifunctional non-tyrosine kinase receptor with an established role in development and immunity. NRP-1 also regulates tumor biology, and high expression levels of tissue NRP-1 have been associated with a poor prognosis. Recently, ELISA-based quantification of soluble NRP-1 (sNRP-1) has become available, but little is known about the prognostic value of sNRP-1 in malignancies.
MATERIALS AND METHODS
METHODS
We measured sNRP-1 in the serum of 509 patients with primary early breast cancer (BC) at the time of diagnosis using ELISA.
RESULTS
RESULTS
Mean serum values of sNRP-1 were 1.88 ± 0.52 nmol/l (= 130.83 ± 36.24 ng/ml). SNRP-1 levels weakly correlated with age, and were higher in peri- and postmenopausal patients compared to premenopausal patients, respectively (p < 0.0001). Low levels of sNRP-1 were associated with a significant survival benefit compared to high sNRP-1 levels at baseline (p = 0.005; HR 1.94; 95%CI 1.23-3.06). These findings remained significant after adjustment for tumor stage including lymph node involvement, grading, hormone receptor, HER2 status, and age (p = 0.022; HR 1.78; 95%CI 1.09-2.91).
CONCLUSION
CONCLUSIONS
Our findings warrant further investigations into the prognostic and therapeutic potential of sNRP-1 in BC.
Identifiants
pubmed: 33884469
doi: 10.1007/s00432-021-03635-1
pii: 10.1007/s00432-021-03635-1
pmc: PMC8236462
doi:
Substances chimiques
Biomarkers, Tumor
0
Neuropilin-1
144713-63-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2233-2238Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : RA 2151/5-1
Organisme : Deutsche Forschungsgemeinschaft
ID : HO 1875/27-1
Références
Dis Markers. 2015;2015:506428
pubmed: 25873749
Biochem J. 2008 Apr 15;411(2):211-26
pubmed: 18363553
Cancer Manag Res. 2018 Jul 11;10:1969-1974
pubmed: 30022855
Clin Cancer Res. 2019 Feb 15;25(4):1369-1378
pubmed: 30425091
Exp Ther Med. 2018 Aug;16(2):537-546
pubmed: 30116312
Oncotarget. 2016 Aug 23;7(34):54723-54732
pubmed: 27351129
J Biol Chem. 2011 Jan 7;286(1):12-23
pubmed: 20956519
J Clin Med. 2020 May 12;9(5):
pubmed: 32408477
Cell. 1998 Mar 20;92(6):735-45
pubmed: 9529250
Oncogene. 2007 Aug 16;26(38):5577-86
pubmed: 17369861
Cancer Res. 2002 Dec 15;62(24):7203-6
pubmed: 12499259
J Pathol. 2012 Jan;226(1):50-60
pubmed: 22025255
Cancer Treat Rev. 2017 Feb;53:79-97
pubmed: 28088073
Cell. 1997 Aug 22;90(4):753-62
pubmed: 9288754
Blood. 2002 Dec 15;100(13):4622-8
pubmed: 12453880
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2573-8
pubmed: 10688880
Adv Exp Med Biol. 2002;515:103-14
pubmed: 12613547
Breast Cancer Res Treat. 2020 Apr;180(2):515-524
pubmed: 32040688
J Leukoc Biol. 2008 Jul;84(1):302-10
pubmed: 18436584
Adv Exp Med Biol. 2002;515:49-54
pubmed: 12613542
Sci Rep. 2017 Jun 12;7(1):3301
pubmed: 28607365
Front Oncol. 2019 Apr 25;9:323
pubmed: 31106153
J Biol Chem. 2002 Jul 5;277(27):24818-25
pubmed: 11986311
PLoS One. 2014 Jul 07;9(7):e101931
pubmed: 24999732
Exp Ther Med. 2013 Jan;5(1):150-154
pubmed: 23251257
Am J Pathol. 2004 Jun;164(6):2139-51
pubmed: 15161648
Pancreas. 2014 Jul;43(5):744-9
pubmed: 24632553
Oncotarget. 2012 Sep;3(9):921-39
pubmed: 22948112
Oncogene. 2017 Jun 15;36(24):3417-3427
pubmed: 28092670
J Clin Invest. 2010 Jul;120(7):2379-94
pubmed: 20577048
MAbs. 2009 Jul-Aug;1(4):364-9
pubmed: 20068394
J Cancer Res Clin Oncol. 2017 Sep;143(9):1701-1712
pubmed: 28429102
Cancer Lett. 2016 Apr 1;373(1):1-11
pubmed: 26805761
Hum Pathol. 2008 Dec;39(12):1835-43
pubmed: 18715621